SP-304 Dose Ranging Study in Patients With Chronic Idiopathic Constipation
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2a, randomized, double-blind, placebo-controlled, 14-day repeat oral, dose
ranging study to determine the safety, pharmacokinetics (PK) and pharmacodynamics (PD)
effects of SP-304 in patients with chronic idiopathic constipation.
Phase:
Phase 2
Details
Lead Sponsor:
Bausch Health Americas, Inc. Synergy Pharmaceuticals Inc.